* Total PML cases at 28 as of Nov. 30, 2009 - Biogen
* Total at end of October was 24
* December figure to be released in week or two
BOSTON, Jan. 6 Biogen Idec Inc (BIIB.O) said on
Wednesday that four more patients taking its multiple sclerosis
drug Tysabri had developed a potentially deadly brain infection
known as PML in November, bringing the total to 28.
The biotech company said it will release the number for
December within a week or two.
Cambridge, Massachusetts-based Biogen makes Tysabri, its
biggest driver of growth, in partnership with Elan Corp Plc
ELN.I of Ireland.
Tysabri was temporarily withdrawn from the market in 2005
after being linked with progressive multifocal
leukoencephalopathy, or PML. It was reintroduced in July 2006
with stricter safety warnings.
The risk rate is still within the rate of 1/1000 listed in
the drug's package insert, Naomi Aoki, a spokeswoman for
Biogen, said .
"While I understand this interest in counting the cases,
one case does not make any impact on the rate at all," she
(Reporting by Toni Clarke; Editing by Gary Hill)